Clinical Trial Update: Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

This clinical trial update reports the termination of a Phase 2 salvage therapy trial using daratumumab, ixazomib, pomalidomide, and dexamethasone for relapsed/…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DARZALEX (daratumumab)
• Decadron (Dexamethasone)
• NINLARO (ixazomib)
• Pomalyst (pomalidomide)

Snippet

Sponsor: University of California, San Diego | Conditions: Relapsed/Refractory Multiple Myeloma | Phase 2 | Status: TERMINATED